
Last updated: 2 months ago
Neumora Therapeutics' Leadership Shake-Up: CEO Transition Report
Neumora Therapeutics (NASDAQ: NMRA) files Form 8-K/A on Feb 13, 2025, detailing CEO transition and strategic changes.
Neumora Therapeutics (NASDAQ: NMRA) files Form 8-K/A on Feb 13, 2025, detailing CEO transition and strategic changes.
Discover Neumora Therapeutics, Inc.'s significant events in their 8-K filing dated February 13, 2025. Stay informed on crucial stock and financial information.
Explore Neumora Therapeutics' 8-K report filed on January 13, 2025, detailing corporate info, stock data, and more.
Discover critical updates from Neumora Therapeutics, Inc. in their January 2, 2025 8-K filing. Stay informed on significant corporate changes and stock performance insights.